Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2004

Study Completion Date

March 31, 2006

Conditions
MelanomaMetastases
Interventions
DRUG

M200 (volociximab) in Combination with Dacarbazine (DTIC)

Trial Locations (7)

29303

Palmetto Hematology Oncology, P.C., Spartanburg

77030

MD Anderson Cancer Center, Houston

85724

Arizona Cancer Center, Tucson

90095

UCLA School of Medicine, Los Angeles

90404

Cancer Institute Medical Group, Inc., Santa Monica

35294-3300

University of Alabama at Birmingham-Comprehensive Cancer Ctr., Birmingham

Unknown

University of Pittsburgh, Pittsburgh

Sponsors
All Listed Sponsors
lead

PDL BioPharma, Inc.

INDUSTRY

NCT00099970 - Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy | Biotech Hunter | Biotech Hunter